vTv Therapeutics Announces First Patient Randomized In Phase 2a Hybrid CATT1 Study Of Cadisegliatin In Type 1 Diabetes

Phase 2a pilot study aims to inform the design and conduct of future 

Phase 3 research in this population

Cadisegliatin is a potential first-in-class oral therapy being evaluated as an adjunct to insulin for the treatment of T1D

HIGH POINT, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (NASDAQ:VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel, investigational oral therapy for type 1 diabetes (T1D), today announced that the first participant has been randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems. The Company expects the results to provide insight into cadisegliatin’s potential in this growing segment of the T1D population and to inform additional clinical studies.

Automated insulin delivery (AID) systems, also called closed-loop or artificial pancreas systems, combine a continuous glucose monitor (CGM), an insulin pump, and a control algorithm to adjust insulin delivery automatically. HCL systems, the most common type of AID, automate basal insulin adjustments but still require the user to, for example, manage insulin dosing for meals or periods of exercise.